Patients with rheumatic disease reported significant employment status changes, which may imply issues with healthcare access, affordable medication, mental health concerns, and rheumatic disease activity. However, they tended to follow public health advice and continued therapy to mitigate the risk of COVID-19 diagnosis.
Compared with controls, patients with psoriatic arthritis presented more often with depression at baseline and patients with rheumatoid arthritis had a higher incidence of cardiovascular comorbidity after 3 years.
Only 11% of patients reported a flare that required treatment and no participants experienced severe flares. Approximately 60% of flares occurred after D2.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 6, 2021.
Although it is assumed that fatigue is related to inflammation, disease activity, or treatment with drugs such as Methotrexate, it can affect children independent of disease activity and impacted by psychosocial factors.
The risk of developing systemic lupus erythematosus (SLE) was reduced by 19% with every increase in a healthy lifestyle index score (HLIS). The risk of dsDNA positive SLE reduced 22% with the addition of each healthy behavior. Those with genetic risk factors may be able to reduce their risk of SLE diagnosis by almost 50% with adherence to healthy lifestyle behaviors.
Researchers call for greater research on the relationship between PTSD and autoimmune diseases in Medicaid patients after finding a troubling association.
In this Q&A, corresponding author Josef S Smolen, MD, discussed the findings of his study determining the effectiveness of ustekinumab versus tumor necrosis factor inhibition in patients with psoriatic arthritis.
The US Food and Drug Administration (FDA) announced the approval of anifrolumab-fnia (Saphnelo™) for the treatment of moderate to severe systemic lupus erythematosus.
Conversations assessing and responding to suicide risk with your patients destigmatizes suicide and mental illness while strengthening your skills as a provider.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 30, 2021.
After controlling for variables, eldery-onset rheumatoid arthritis (EORA) was not indicative of changes in Clinical Disease Activity Index (CDAI) scores over time when compared with a non-EORA cohort. Further, there were no significant differences in the efficacy and safety of receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
“Our study confirms challenges in selecting an appropriate outcome in interventional studies targeting medication adherence and the ways in which the lack of guidance in this area hinders research and limits our ability to compare interventions and draw conclusions about their effectiveness,” stated investigators.
Common immunosuppressant therapies for patients with rheumatic disease, such as methotrexate and targeted biologics, increase risk of serious infection, especially with respiratory pathogens. A recent study investigates the connection between these drugs and functional humoral immunity to the first dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).
A recent statement by Regeneron noted that chronic spontaneous urticaria is the fifth disease associated with positive Phase 3 results involving the monoclonal antibody.
Researchers record more depressive symptoms in patients with psoriatic arthritis, which they believe incentivizes doctors to utilize screening methods that focus on the mental health of a patient.
Many children with juvenile idiopathic arthritis stop vaccinating when diagnosis is established, despite them being at a greater risk of infections than healthy children due to their aberrant immunity and the use of immunosuppressive drugs.
While prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA) is advocated by recent recommendations, ASCVD prevention in patients with RA was underwhelming, according to an international audit.
Investigators from Turkey show how static foot posture in patients with rheumatic diseases can lead to impairment of physical function due enthesitis.
Guselkumab, an interleukin-23p19-subunit inhibitor, led to clinically significant and sustained improvements in fatigue through 1 year in patients with active psoriatic arthritis.
A study from the University of South Australia assessing the impact of high-dose, short-term caffeine consumption suggests increased consumption could increase renal calcium clearance by 77% in healthy patients.
Patients with systemic lupus erythematosus presented more cardiovascular autonomic neuropathy, along with impaired health-related quality of life and parasympathetic function, when compared with a control cohort.
The newest FDA indication allows for greater distribution to younger but equally vulnerable immunocompromised patients.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 23, 2021.
Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.
Researchers from Texas determined the global prevalence of OSA using 8 unique studies involving patients with rheumatoid arthritis from around the world.
The painTRAINER program included 8 weekly modules, in addition to coping skill activities, in which investigators measured outcomes including the Pain Catastrophizing Scale, pain interference, physical function, anxiety and depression, fatigue, and sleep disturbances.
Using data from more than 2000 patients followed for 16 years, a Garvan Institute of Medical Research-led team found cognitive decline in older women could help predict bone loss and fracture risk among these patients.
Researchers from France challenge previous reports of the IL-17 inhibitor treatment resulting in an increased risk of inflammatory bowel disease in patients with immune disorders like psoriasis.
